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Abstract 
Background: The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment 
of malaria in pregnancy (MiP) with sulfadoxine–pyrimethamine (IPTp‑SP) across Africa. However, there is no rec‑
ommended alternative medicine for IPTp or alternative strategy for prevention of MiP. This poses problems for the 
prevention of MiP. This study investigated, whether screening with a rapid diagnostic test for malaria at routine ante‑
natal clinic attendances and treatment of only those who are positive (intermittent screening and treatment) with 
artemether–lumefantrine is as effective and safe as IPTp‑SP in pregnant women.
Methods: During antenatal clinic sessions at the General Hospital Calabar, Nigeria, held between October 2013 and 
November 2014, 459 pregnant women were randomized into either the current standard IPTp‑SP or intermittent 
screening and treatment with artemether–lumefantrine (ISTp‑AL). All women received a long‑lasting insecticide‑
treated net at enrolment. Study women had a maximum of four scheduled visits following enrolment. Haemoglobin 
concentration and peripheral parasitaemia were assessed in the third trimester (36–40 weeks of gestation). Birth 
weight was documented at delivery or within a week for babies delivered at home.
Results: In the third trimester, the overall prevalence of severe anaemia (Hb < 8 g/dl) and moderate (8–10.9 g/dl) 
anaemia was 0.8 and 27.7%, respectively, and was similar in both treatment groups (p = 0.204). The risk of third‑trimes‑
ter severe anaemia did not differ significantly between both treatment arms (risk difference − 1.75% [95% CI − 4.16 
to 0.66]) although the sample was underpowered for this outcome due to several participants being unavailable to 
give a blood sample. The risk of third‑trimester maternal parasitaemia was significantly lower in the ISTp‑AL arm (RD 
− 3.96% [95% CI − 7.76 to − 0.16]). The risk of low birthweight was significantly lower in the ISTp‑AL arm after control‑
ling for maternal age, gravidity and baseline parasitaemia (risk difference − 1.53% [95% CI − 1.54 to − 1.15]). Women 
in the ISTp‑AL arm complained of fever more frequently compared to women in the IPTp‑SP arm (p = 0.022).
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Background
Malaria in pregnancy (MiP) remains a significant pub-
lic health concern with over 32 million women at risk 
every year [1]. MiP has deleterious consequences for 
the mother and her fetus. Some of the well-known 
adverse effects include maternal anaemia, stillbirth, 
intrauterine growth retardation, low birth weight and 
preterm deliveries [2–4]. Malaria incidence and deaths 
have declined globally with about 214 million cases and 
438,000 deaths reported in 2015 representing declines 
of 18 and 48% from the year 2000 [5]. These declines 
have been attributed to sustained scale-up and cover-
age of preventive interventions such as the use of long-
lasting insecticide-treated nets (LLINs), vector control, 
prompt diagnosis with rapid diagnostic tests (RDTs) 
and effective treatment mainly with artemisinin-based 
combination therapy (ACT) [5, 6].
The World Health Organization (WHO) currently 
recommends a package of interventions to prevent MiP 
in areas with stable transmission in sub-Saharan Africa 
(SSA). These interventions include the use of LLINs, 
effective treatment and intermittent preventive treat-
ment with sulfadoxine–pyrimethamine (IPTp-SP) given 
at scheduled antenatal visit beginning as early as pos-
sible in the second trimester [7].
Intermittent preventive treatment with sulfadox-
ine–pyrimethamine (SP) is very effective at reducing 
the adverse outcomes of MiP, but is threatened by the 
emergence of widespread parasite resistance [8, 9]. 
IPTp-SP has even been documented to cause harm by 
increasing placental proliferation of resistant parasites 
in pregnant women [10]. Mefloquine and a combina-
tion of azithromycin and chloroquine have been inves-
tigated as alternatives to SP for IPTp but were both 
poorly tolerated and thus not recommended for use 
in IPTp [11]. More recently, dihydroartemisinin-pipe-
raquine (DHA-P) showed promising results as an alter-
native drug to replace SP for intermittent preventive 
treatment. However, further investigations are required 
to establish its safety and effects on birth outcome [12]. 
Thus there are currently no alternative drugs recom-
mended for use in IPTp.
An alternative approach to IPTp-SP is intermittent 
screening and treatment in pregnancy (ISTp), which 
involves screening women for malaria with a rapid diag-
nostic test (RDT) during routine antenatal clinic visits 
and treatment of positives with an effective anti-malarial 
combination, e.g. an artemisinin-based drug combina-
tion. Two trials conducted in West Africa (Burkina Faso, 
Ghana, Mali, and The Gambia) have shown ISTp to be 
non-inferior to IPTp-SP in preventing low birth weight 
and maternal anaemia and placental malaria [11, 13]. 
Also, testing pregnant women for malaria before treat-
ment encourages rational use of anti-malarial drugs 
and reduces drug pressure, which should slow down the 
development of parasite resistance.
This trial investigated whether ISTp-AL was non-
inferior to IPTp-SP in the prevention of anaemia in 
pregnancy in an area of Nigeria with perennial malaria 
transmission.
Methods
Ethics
Participation in the study was voluntary; subjects were 
free to withdraw from the study at any time, and this did 
not affect their access to or quality of care. Information 
obtained from all subjects was treated as confidential. 
The trial was conducted under the provisions of the Dec-
laration of Helsinki in its most recent form (2013) and in 
accordance with Good Clinical Practices guidelines set 
up by the WHO and by the International Conference on 
Harmonization.
The purpose of the study, the procedures to be fol-
lowed and the potential risks, as well as benefits of par-
ticipation, were explained to all participants. Information 
sheets and consent forms were provided to them for their 
review. Each participant signed an informed consent to 
participate in the research study.
The study protocol and informed consent forms 
were reviewed and approved by the Cross River Health 
Research Ethics Committee, Calabar, Nigeria and the 
Ethics Board of the Medical Center of the University of 
Munich (LMU), Munich, Germany. The trial was pro-
spectively registered with the Pan African Clinical Trials 
Registry (PACTR201308000543272).
Conclusions: The trial results suggest that in an area of high malaria transmission with moderate sulfadoxine–
pyrimethamine resistance, ISTp with artemether–lumefantrine may be an effective strategy for controlling malaria in 
pregnancy.
Trial registration PACTR, PACTR201308000543272. Registered 29 April 2013, http://www.pactr .org/ATMWe b/appma 
nager /atm/atmre gistr y?dar=true&tNo=PACTR 20130 80005 43272 
Keywords: Intermittent screening and treatment, Malaria in pregnancy, Intermittent preventive treatment, 
Artemether–lumefantrine, Sulfadoxine–pyrimethamine
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Study design
This study was an individually randomized, two-arm, 
observer-blinded, parallel-group, non-inferiority trial. 
The trial was undertaken between October 2013 and 
November 2014 to investigate whether screening for 
malaria with RDT and treating all women with a posi-
tive result using AL was not inferior to intermittent pre-
ventive treatment with SP in the prevention of anaemia 
in pregnancy. Eligible and consenting pregnant women 
were randomly assigned (1:1) to one of the two study 
arms (1) LLIN plus IPTp-SP or (2) LLIN plus ISTp-AL.
Study population
The study was conducted in Calabar, Cross River State 
in South-East Nigeria. In the 2006 Population and Hous-
ing Census, Cross River state was made up of 1,471,967 
males and 1,421,021 females with an annual growth rate 
of 2.9%. The projected population for 2015 is 3,783,085.
The climate in Calabar is tropical-humid with wet and 
dry seasons, with average temperatures ranging between 
15 and 30  °C and the annual rainfall between 1300 and 
3000 mm. The vegetation in Calabar is mangrove swamp 
forest. Malaria transmission in this area is intense and 
perennial but with a peak in the rainy season, and Plas-
modium falciparum is the predominant malaria-causing 
species [5, 14].
Previous studies have reported resistance to CQ and SP 
in Calabar to be over 80% [15]. Anopheles gambiae is the 
predominant vector species [16]. There is no information 
available on entomological inoculation rate (EIR) in the 
study area, but an EIR of about 259 infectious bites per 
person-year has been reported from Odukpani, a neigh-
bouring area [17]. National HIV prevalence is reported 
to be about 3.4% with a higher prevalence of 5.5% in the 
region where the trial was conducted [18].
The trial was conducted at the antenatal clinics of the 
General Hospital in Calabar, Nigeria. The General Hos-
pital is the largest government-owned secondary health 
facility in the city and caters to the health needs of the 
majority of the inhabitants. Since August 2009, preg-
nant women and children under 5  years of age receive 
free medical care as part of a funded welfare program by 
the Cross River State government. The average annual 
antenatal clinic attendance and births at the hospital 
are 16,550 and 3100 respectively. In the study area, the 
proportion of births attended by unskilled personnel 
has been estimated to be about 85% [19, 20]. In a health 
demographic and surveillance area 15 km from the trial 
site, only about 15% of births take place in health facili-
ties [21].
The study population comprised pregnant women of 
all parities who presented at the antenatal clinics at their 
first booking. Antenatal care clinics were conducted 
3 days per week; Wednesdays for first visits, then Mon-
days and Thursdays for follow-up visits. Women were 
screened for eligibility and invited to participate in the 
study if they met the criteria. Eligible participants were 
HIV-negative pregnant women between 16 and 24 weeks’ 
gestation at their first booking, no history of receiv-
ing intermittent preventive treatment with sulfadox-
ine–pyrimethamine during the pregnancy, resident in 
the study area, and willing to have a supervised delivery. 
Women with any illness requiring hospital admission 
(including severe malaria as defined by WHO), high-risk 
pregnancies, severe anaemia (Hb < 6 g/dl), known G6PD 
deficiency, a history of sensitivity to SP, lumefantrine or 
an artemisinin, or those unwilling to give consent were 
excluded.
Sample size
The sample size was calculated based on the assump-
tion that the prevalence of severe anaemia in the third 
trimester of pregnancy in the IPTp-SP arm of the study 
would be at least 3% based on findings from a previous 
study undertaken in West Africa [13]. Due to widespread 
resistance to SP, it was hypothesized that the preva-
lence of severe anaemia would be significantly lower in 
the LLIN plus ISTp-AL arm compared to the LLIN plus 
IPTp-SP arm. To establish that ISTp-AL was not infe-
rior to IPTp-SP, it was necessary to show that the differ-
ences in the proportion of women with severe anaemia 
between both arms would not be more than 5%, a differ-
ence which would be of clinical and public health impor-
tance. To meet these criteria with 80% statistical power 
and allowing for 20% loss to follow-up it was calculated 
that 230 women were needed in each study arm giving a 
total sample size of 460.
Procedures
All pregnant women presenting for their first antena-
tal care visit at the General Hospital were invited to 
attend group information sessions and were screened 
for their eligibility. After women had provided writ-
ten informed consent, they were randomised to one of 
the two treatment groups (ISTp-AL or IPTp-SP arm) in 
computer-generated permuted blocks of ten. At enrol-
ment, an eligible pregnant woman (16–24  weeks gesta-
tional age) was asked by a designated study nurse to pick 
a slip from the opaque envelope. The slip contained the 
treatment group the woman had been assigned to. The 
study arm women belonged to was not identifiable by 
the identification numbers given to them. Also, the prin-
cipal investigator and outcome assessors (midwives and 
microscopist) were blinded to the randomization pro-
cess and treatment allocation to prevent bias in outcome 
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assessment. Women who declined to participate in the 
trial were treated with the routine standard of care, IPTp-
SP according to the national guidelines. Enrolled study 
women were randomized to either the ISTp-AL or IPTp-
SP arm.
All study women received a LLIN, which they were 
encouraged to use throughout the pregnancy. Also, they 
received a daily supplement of folic acid (4 mg) and fer-
rous sulphate (200  mg) tablets according to national 
guidelines. HIV screening was offered to all study women 
as part of the routine antenatal services recommended in 
Nigeria with an option for treatment, but the results of 
HIV screening were not available to the study team at the 
time of enrolment.
At enrolment, a finger prick blood sample was 
obtained for determination of haemoglobin concentra-
tion, preparation of blood smears (thin and thick films) 
for malaria parasite counts and preparation of dried 
blood spots (DBS) on filter paper. Women in the IPTp-
SP arm received an initial dose of SP (1500 mg sulfadox-
ine/75  mg pyrimethamine) as a single dose. Pregnant 
women in ISTp-AL arm were screened for malaria infec-
tion with an SD Bioline rapid diagnostic test (RDT), a 
histidine-rich protein-2 (HRP-II) antigen and Plasmo-
dium lactate dehydrogenase (pLDH) (Pan) antigen RDT 
kit. The RDTs were purchased from Codex Pharma 
Limited, Nigeria, as needed and stored following the 
manufacturer’s instructions. The tests were also per-
formed and interpreted by the study team following the 
manufacturer’s instructions. Women in the ISTp-AL 
arm were treated with artemether–lumefantrine (20 mg 
artemether/120  mg lumefantrine) given as a 6-dose 
course, administered twice daily for 3  days if the RDT 
was positive. Study women were advised on the time and 
mode of administration for the 3 days treatment taken at 
home unobserved. Women in the ISTp-AL arm received 
no anti-malarial treatment if their RDT results were 
negative.  Laridox® (sulfadoxine–pyrimethamine, IPCA 
Laboratories Ltd, India) and  Coartem® (artemether–
lumefantrine, Novartis Pharma, Switzerland) were used 
for this trial.
Study women were asked to return for follow-up ante-
natal care visits and IPTp-SP or screening with RDT 
at 24, 32 and 36  weeks of gestation if they were in the 
ISTp-AL group. At the next two follow-up visits (at 24 
and 32  weeks of gestation), women in the IPTp-SP arm 
received SP while women in the ISTp-AL arm were 
screened with the RDT and, if positive, treated with AL. 
All women were followed-up by a study nurse through 
phone calls and at subsequent visits to document any 
complaints or adverse events.
Study women were also provided with a mobile phone 
number, which they could call to arrange unscheduled 
visits. Blood samples were obtained from all women 
in the third semester (36–40  weeks of gestation) before 
delivery for the determination of haemoglobin concen-
tration and the preparation of blood smears. However, 
the smears were read retrospectively, and so the results 
were not available at the point of care. At delivery, pla-
cental smears were collected on microscopy slides to 
determine the prevalence of placental malaria. Study 
woman who came to the hospital with a history of fever 
or other symptoms of malaria between scheduled ante-
natal care visits was screened for malaria with RDT and if 
positive for malaria, treated with quinine (30 mg/kg daily 
for 5  days) regardless of treatment group according to 
national policy.
Birth weight was measured by a midwife who was 
unaware of the treatment group of the woman whom 
she was attending. The occurrence of miscarriages, still-
births, neonatal deaths and the presence of congenital 
abnormalities were also recorded by midwives. Women 
were invited to re-attend at 6  weeks postpartum with 
their baby. A blood film was obtained from the mother. 
Her haemoglobin concentration was also measured at 
this time. Also, any neonatal adverse events were docu-
mented. A team of nurses, lab scientists was dedicated to 
the follow-up of women who did not present for delivery 
at the General hospital within 1 month of the estimated 
delivery date to establish pregnancy outcome.
Laboratory evaluations
Labelled blood and impression smears were air-dried 
and stained with 4% Giemsa for 30  min. Thick smears 
were used to count the number of asexual parasites per 
200 leukocytes, assuming 8000  leukocytes/μl of blood; 
slides were declared negative if no parasite was seen after 
examination of 100 high power fields. All blood films 
were read, and parasitaemia was quantified by two expe-
rienced and blinded microscopists independently. If there 
was a discrepancy in the findings in a slide between the 
two microscopists (positive or negative or a ≥ 50% differ-
ence in parasite density) a third, more senior microsco-
pist read the slide and their reading was deemed to be the 
correct reading. Haemoglobin (Hb) concentration was 
measured using Hb 301 Hemocue (HemoCue AB, Angel-
holm, Sweden; accuracy of 0.1 g/dl).
Adverse events monitoring and reporting
Case report forms were completed for maternal, and neo-
natal adverse events (AEs) detected at scheduled ante-
natal and postpartum visits, at unscheduled visits and 
delivery. The clinician on-call was alerted by the nursing 
team upon detection of a possible serious adverse event 
(SAE). AEs were considered SAEs if they fulfilled one of 
the following criteria: the event resulted in death, led to 
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hospitalization, was a congenital abnormality, was life-
threatening, caused disability, or was deemed serious for 
other medical reasons.
Serious adverse event reports were completed for study 
women who experienced miscarriages or stillbirths. Sig-
nificant reductions in haemoglobin concentration (≤ 6 g/
dl) after enrolment were also considered SAEs. Reports 
of drug side effects at each treatment course were consid-
ered as separate AEs.
Statistical methods
Stata version 12 (StataCorp, College Station, Texas) was 
used for data analyses. The primary objective of the trial 
was to show that the risk of third-trimester severe anae-
mia (Hb ≤ 8  g/dl) in the ISTp-AL group was no more 
than 5% greater than in the IPTp-SP group. Second-
ary objectives were to demonstrate that the risks of low 
birth weight (< 2500  g), intrauterine deaths/stillbirths, 
spontaneous abortions, neonatal and maternal mortality 
were not significantly higher in women in the ISTp-AL 
group than in women who received IPTp-SP. The prin-
cipal analysis of both primary and secondary outcomes 
was according-to-protocol (ATP), but a modified inten-
tion-to-treat (mITT) analysis was also undertaken. In 
the ATP analysis, only data from women who remained 
within their randomization group and had a record of the 
primary outcome were included. This implied that study 
women had to have received two courses of SP (IPTp-SP 
arm) or been screened twice using an RDT at scheduled 
visits (ISTp-AL arm) and also, had a measurement for 
the primary outcome (haemoglobin level at 36–40 weeks 
gestation).
In the modified intent-to-treat analysis (mITT), data 
from women who received an initial treatment of IPTp 
or had an initial screening test done and had a record for 
the primary outcome or the outcome of interest recorded 
was included. This implied that study women had to 
have received one course of SP (IPTp-SP arm) or been 
screened once using an RDT at scheduled visits (ISTp-AL 
arm) and also, have a measurement for the primary out-
come or outcome of interest.
The proportion of ATP and mITT populations experi-
encing each outcome for the trial arms, and the associ-
ated 2-sided 95% CI for the risk difference, was estimated 
using the generalized linear model. To declare non-inferi-
ority with a significance level of 0.05, the upper boundary 
of the 2-sided 95% CI for the estimated treatment effect 
had to be below the pre-defined non-inferiority margin 
(∆) of 5%. Gestational age at enrolment, being primi-
gravidae, baseline anaemia and parasitaemia were con-
trolled for using binomial regression.
Only birth weights from singleton pregnancies of 
live births ≥ 22  weeks’ gestation with no congenital 
abnormality and measured within 6 days of delivery were 
included in birth weight analyses. p-values less than 0.05 
were considered statistically significant.
Results
Baseline demographic and clinical characteristics
A total of 460 of the 593 (77.6%) potentially eligible preg-
nant women who were screened were enrolled into either 
the IPTp-SP arm or the ISTp-AL arm (Fig. 1). Of the 133 
women excluded at the screening stage, 41 did not meet 
inclusion criteria while 92 women declined participation 
in the study. 459 study women completed the first visit 
(i.e. received an initial treatment of IPTp with SP or had 
had an initial screening test done).
Baseline characteristics of study women in both treat-
ment groups were very similar at enrolment (Table  1). 
About three-quarters of the study women in both arms 
were aged between 13 and 30 years with an overall mean 
age of 28.2 years. All study women had some level of for-
mal education, and over 90% of them had been educated 
up to at least secondary level.
The majority of the study women were students in ter-
tiary institutions. Only 22% of the study women were 
salary workers comprised mainly of civil servants and 
teachers. Fifty-seven percent of the study population 
households already owned a bed net. However self-
reported bed net use the night preceding enrolment was 
about 15%. Forty-seven percent of study women were 
primigravidae, and 29% were multigravidae.
1.1% of women had a haemoglobin concentration 
below 8  g/dl; the overall mean Hb concentration was 
11.5 g/dl. Asymptomatic parasitaemia as determined by 
microscopy was found in 7.0% (32/459) of study women 
overall with parasite densities less than 500/ml in about 
37.5% (12/32). The PCR-adjusted malaria prevalence at 
enrolment was 6.3% (29/459). The prevalence of malaria 
infection at enrolment in women in the ISTp-AL arm as 
determined by the SD  Bioline® rapid diagnostic test was 
11.3% (RDTs were not done in women in the IPTp-SP 
arm). Baseline anaemia was significantly associated with 
asymptomatic malaria parasitaemia (p < 0.001). Plasmo-
dium falciparum was the common malaria species. One 
mixed infection of Plasmodium malariae and P. falci-
parum was observed. The overall prevalence of HIV in 
pregnant women who were enrolled during the period of 
the trial was 1.3%
Study outcomes‑according to protocol (ATP) analysis
At the end of follow-up, 239 (51.9%) evaluable records 
for third-trimester haemoglobin concentration and 329 
(71.5%) records for birth weight were available. Informa-
tion on the outcome of pregnancy was obtained for 420 
of the 459 study women (91.5%), 331 (72.1%) of whom 
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delivered at a health centre or hospital and 58 (12.6%) at 
home. Three women withdrew from the study (two in the 
IPTp-SP arm and one in the ISTp-AL arm).
In the third trimester before delivery, the overall 
prevalence of severe anaemia (Hb < 8  g/dl) and moder-
ate (8–10.9  g/dl) anaemia was 0.8 and 27.7% respec-
tively (Table 2) and was similar in both treatment groups 
(p = 0.142). Throughout pregnancy, the overall preva-
lence of asymptomatic parasitaemia based on microscopy 
and PCR were 4 and 4.2%, respectively.
The mean haemoglobin concentration of all women 
between 36 and 40  weeks of gestation was 11.5  g/dl. 
The mean HB concentration in the ISTp-AL and IPTp-
SP groups were 11.7 and 11.4  g/dl, respectively. How-
ever, this difference was not statistically significant 
(p = 0.073). There was a non-significant increase in mean 
haemoglobin concentration of 0.05  g/dl at 36–40  weeks 
of gestation over the baseline haemoglobin concentra-
tion (p = 0.54) (Fig.  2). There was no significant differ-
ence in haemoglobin concentration during the course of 
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6 Sll birth 
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Fig. 1 Trial profile showing enrolment and follow‑up status of study women
Page 7 of 12Esu et al. Malar J  (2018) 17:251 
pregnancy between the two trial arms. The risk of third-
trimester severe anaemia (Hb < 8 g/dl) did not differ sig-
nificantly between both treatment groups (risk difference 
− 1.75% [95% CI − 4.16 to 0.66]. The upper boundary 
of the 2-sided 95% CI for the risk difference estimated 
between the ISTp-AL and IPTp-SP groups was below 
the non-inferiority margin of 5% set for third-trimester 
severe anaemia.
The risk of parasitaemia in the third trimester (36–
40  weeks of gestation) was significantly higher in the 
IPTp-SP arm than in the ISTp-AL arm (Table  2). The 
risk difference for parasitaemia between the ISTp-
AL and IPTp-SP groups was − 3.96% [95% CI − 7.76 
to − 0.16]. One episode of illness associated with 
malaria parasitaemia was recorded in the IPTp-SP arm, 
throughout the trial. In all 531 RDT tests that were 
Table 1 Comparison of demographic and baseline characteristics of study women
Variable SP‑IPTp ISTp‑AL Total
(N = 229) (N = 230) (N = 459)
n (%) n (%) n (%)
Age (years)
 ≤ 25 58 25.3 76 33 135 29.4
 26–30 103 45 86 37.4 189 41.0
 ≥ 31 68 29.7 68 29.6 136 29.6
 Mean (SD) 28.4 (4.6) 27.9 (5.4) 28.2 (5.0)
 Median (IQR) 28 (6) 28 (7) 28 (6)
Educational attainment
 Primary 7 3.1 6 2.6 13 2.8
 Secondary 96 41.9 99 43 195 42.5
 Tertiary 126 55 125 54.4 251 54.7
Occupation
 None 10 4.4 21 9.1 31 6.8
 Student 49 21.4 46 20 95 20.6
 Housewife 26 11.4 24 10.4 50 10.9
 Small business owner 92 40.1 90 39.1 182 39.7
 Salary worker 52 22.7 49 21.3 101 22
Gravidity
 Primagravidae 107 46.7 109 47.4 216 47.0
 Secundigravidae 68 29.7 69 30.0 137 29.9
 Multigravidae 54 23.6 52 22.6 106 23.1
Household ownership of bed net
 No 99 43.2 108 47 207 45.1
 Yes 130 56.8 122 53 252 54.9
Slept under bed net (previous night)
 No 197 86. 195 84.8 392 85.4
 Yes 32 14 35 15.2 67 14.6
Baseline parasitaemia
 No 212 92.6 206 89.6 418 91.1
 Yes 17 7.4 15 6.5 32 7.0
 Parasite density geometric 
mean [95% CI]
954.8 [490.4–1859.3] 951 [452.5–1998.5] 953 [597.3–1520.6]
Haemoglobin (g/dl)
 ≥ 11 135 59 165 71.7 300 65.4
 8–10.9 92 40.2 62 27.0 154 33.5
 < 8 2 0.8 3 1.3 5 1.1
 Mean (SD) 11.4 (1.4) 11.6 (1.3) 11.5 (1.4)
 Median (IQR) 11.3 (1.8) 11.6 (1.4) 11.5 (1.6)
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done in women in the ISTp-AL treatment group, a total 
of 37 (7%) were positive and led to treatment.
The prevalence of placental malaria at delivery as 
determined by microscopy was low with only one low-
density infection found out of 46 (10%) samples col-
lected from study women.
The overall prevalence of low birth weight was 5.9% 
in the study women and did not differ significantly 
between the two trial groups, although the trial was 
not powered to investigate non-inferiority for this out-
come (Table 2). The risk difference for low birthweight 
between the ISTp-AL and IPTp-SP arms was (risk dif-
ference − 1.03% [95% CI − 6.53 to 4.46]. In an adjusted 
analysis which controlled for maternal age, gravidity 
and baseline parasitaemia, the risk difference for low 
birthweight was (risk difference − 1.53% [95% CI − 1.54 
to − 1.15] and significantly lower in the ISTp-AL arm 
(p < 0.001).
The risk of anaemia (severe or moderate) was compara-
ble between both treatment groups (Table 2). Primigravi-
dae women were significantly associated with a lower 
risk of anaemia compared to secundi- and multigravidae 
in univariate analysis. In a multivariate analysis, which 
adjusted for baseline anaemia, treatment group, maternal 
age, and baseline parasitaemia, primigravidae remained 
significantly associated with lower risk of anaemia in the 
third trimester (Table 3).
The risk of moderate anaemia (< 11 g/dl) was similar in 
the ISTp-AL group compared to IPTp-SP; (RD = − 6.1% 
[95% CI − 17.9 to 5.8]. In the adjusted analysis, the risk 
difference was − 5.4% [95% CI − 17.0 to 6.2]. All malaria 
infections were mild, and thus no study woman was 
admitted to hospital.
The risk of low birth weight did not differ significantly 
between both trial arms regardless of gravidity (Table 2). 
Baseline parasitaemia in pregnant women was not signifi-
cantly associated with the low birth weight of their babies 
(Table 4). None of the study women with low birthweight 
babies had severe anaemia at enrollment.
The risks of third-trimester anaemia and low birth 
weight in women who were RDT negative through-
out pregnancy and did not receive AL treatment were 
similar to that of women in the IPTp-SP arm (data not 
shown, see Additional file  1). The most frequent com-
plaints since the last ANC visit by study women were 
headache, cough, catarrh, vomiting and dizziness. These 
symptoms were not significantly different between both 
treatment groups. However, women in the ISTp-AL arm 
Table 2 Comparison of the main outcomes in women enrolled in IPTp-SP and ISTp-AL arms (at 36–40 weeks gestation 
and birth)
Outcome ATP analysis mITT analysis
Control (IPTp‑SP) Intervention (ISTp‑AL) p‑value Control (IPTp‑SP) Intervention (ISTp‑AL) p‑value
Severe anaemia (Hb < 8 g/dl) 2/114 (1.7) 0/124 (0) 0.133 2/115 (1.7) 0/124 (0) 0.142
Moderate anaemia (Hb 8–10.9 g/dl) 36/114 (31.6) 30/124 (24.2) 36/115 (31.3) 30/124 (24.2)
Hb ≥ 11 g/dl 76/114 (66.7) 94/124 (75.8) 77/115 (67) 94/124 (75.8)
Mean haemoglobin g/dl (SD) 11.4 (1.3) 11.7 (1.2) 0.073 11.4 (1.4) 11.7 (1.2) 0.076
Birth weight
 Normal (≥ 2.5 kg) 130/139 (93.5) 139/147 (94.6) 0.712 148/158 (93.7) 157/167 (94) 0.898
 Low (< 2.5 kg) 9/139 (6.5) 8/147 (5.4) 10/158 (6.3) 10/167 (6.0)
 Mean (SD) 3.21 (0.51) 3.18 (0.54) 0.062 3.21 (0.53) 3.17 (0.53) 0.497
 Median (IQR) 3.2 (0.6) 3.2 (0.6) 3.2 (0.6) 3.2 (0.6)
Parasitaemia
 Peripheral blood (light micros‑
copy)
All infections
4/96 (4.2) 2/112 (1.8) 0.304 4/96 (4.2) 2/112 (1.8) 0.304
Fig. 2 Variation of haemoglobin concentration between enrolment 
and third trimester (36–40 weeks gestation)
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complained of fever since their last antenatal clinic visit 
more frequently than in the IPTp-SP arm (p = 0.022) 
(Table  5). Of the nine participants that had a fever, 
seven were in the ISTp-AL arm. Three of these seven 
participants in the ISTp-AL arm had malaria infections 
at the time.
There were no statistically significant differences for 
preterm deliveries, abortions or perinatal deaths between 
Table 3 Factors associated with third-trimester anaemia (< 11 g/dl) in study women (ATP analysis)
CI confidence interval
a p ≤ 0.05 means observed differences between comparison groups is statistically significant or not significant if p > 0.05
b Risk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and gravidity were included in the final model
Unadjusted Risk 
Ratio
(95% CI)a p‑valueb Adjusted Risk 
Ratio
(95% CI) p‑value
Treatment group
 ISTp‑AL 0.83 0.57–1.20 0.318 0.81 0.57–1.17 0.259
 IPTp‑SP 1 1
Age category
 ≤ 25 1 1
 26–30 1.07 0.67–1.72 0.766 0.95 0.59–1.52 0.824
 ≥ 31 1.31 0.81–2.12 0.279 1.03 0.61–1.75 0.899
Baseline parasitaemia
 Yes 1.49 0.90–2.45 0.119 1.46 0.89–2.41 0.138
 No 1 1
Gravidity
 Primigravidae 0.57 0.38–0.87 0.008 0.59 0.37–0.93 0.024
 Secundigravidae 0.67 0.42–1.08 0.104 0.66 0.41–1.06 0.087
 Multigravidae 1 1
Table 4 Factors associated with low birth weight of babies delivered by study women (ATP analysis)
CI confidence interval
a p ≤ 0.05 means observed differences between comparison groups is statistically significant or not significant if p > 0.05
b Risk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and mild anaemia, and gravidity were included in the 
final model
Unadjusted RR (95% CI) p‑valuea Adjusted  RRb (95% CI) p‑value
Treatment group
 ISTp‑AL 0.84 0.33–2.12 0.712 0.84 0.33–2.17 0.72
 IPTp‑SP 1 1
Age category
 ≤ 25 1 1
 26–30 1.17 0.37–3.77 0.787 1.43 0.44–4.59 0.548
 ≥ 31 1.08 0.30–3.86 0.911 2.22 0.58–8.42 0.242
Baseline parasitaemia
 Yes 1.46 0.35–5.99 0.603 1.62 0.39–6.63 0.505
 No 1
Baseline mild anaemia
 Yes 1.32 0.52–3.37 0.558 1.41 0.53–3.70 0.489
 No 1
Gravidity
 Primigravidae 3.18 0.73–13.81 0.123 4.54 0.94–21.84 0.059
 Secundigravidae 1.31 0.23–7.65 0.761 1.44 0.24–8.69 0.694
 Multigravidae 1
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both study arms (Additional file 2). There was one mater-
nal death in the SP-IPTp arm. The death occurred after 
her second visit at 30 weeks gestation. It was not possible 
to establish the cause of death. No drug-related serious 
adverse event occurred.
Modified intention to treat analysis
All the primary and secondary outcomes were also ana-
lysed using modified intention to treat analysis with 
similar results to those of the ATP analysis. For the key 
outcomes of anaemia and low birth weight, there were no 
significant differences as with ATP analysis (Table 2). The 
overall prevalence of parasitaemia at 36–40 weeks gesta-
tion was 1.88%. There was also significantly higher para-
sitaemia in the IPTp-SP arm compared to the ISTp-AL 
arm (p = 0.034). Factors associated with third-trimester 
anaemia and low birth weight are included in additional 
data (Additional files 3 and 4).
Discussion
This trial has demonstrated that ISTp using AL was not 
inferior to IPTp with SP in preventing severe maternal 
anaemia. The study also showed a significantly lower 
risk of parasitaemia in pregnant women and low birth 
weight in newborns of mothers in the ISTp-AL arm. The 
incidence of preterm deliveries, abortions and perinatal 
deaths was similar in both study groups.
About 43% of study women did not contribute data on 
third-trimester anaemia (primary outcome) but contrib-
uted data to the birth weight analysis. This is attributable 
to several national strikes embarked upon by different 
cadres of health workers. These adversely affected follow-
up visits and the recording of related outcomes as the 
health facility was locked up over these periods. Thus, 
the results obtained for third-trimester anaemia are likely 
not powered to exclude clinically significant differences 
based on the sample size calculation, and non-inferiority 
margin set a priori. However, the ATP and mITT analy-
ses yielded similar results and loss to follow-up was 8.5%, 
and there was no significant difference in numbers of 
women lost to follow-up between the treatment arms.
The overall incidence of malaria and severe anaemia 
in study women was observed to be much lower than 
expected and relative to previously reported estimates 
[22–24]. All the malaria infections among study women 
were mild with none requiring hospital admission. Apart 
from the fact that pregnant women often have low-den-
sity asymptomatic malaria infections this finding may be 
explained by continued decline in malaria cases and the 
sustained scale-up in coverage of preventive interven-
tions, including LLIN. All study women received LLIN 
at enrolment and were encouraged to continue sleep-
ing under them at scheduled follow-up visits. The Cross 
River State government has also provided free medical 
care to pregnant women and under-fives since 2009.
The ISTp intervention was well received by most preg-
nant women and health providers in this study. This is 
similar to findings from a trial in West Africa [25]. How-
ever, a few study women withdrew consent from this 
study as a result of the repeated blood draws and finger 
pricks. However, ISTp-AL is likely to be more expensive 
than IPTp-SP because of the cost of RDTs and doses of 
artemether–lumefantrine, which are higher than the cost 
of a dose of SP. AL is also more complex to administer 
being a three-day treatment. Thus, adherence monitoring 
is more difficult and would mostly rely on self-report by 
pregnant women or home visits by health workers.
The transmission of malaria parasites from humans to 
mosquitoes requires the presence of infectious game-
tocytes in the human peripheral blood. Consequently, 
pregnant women with asymptomatic parasitaemia could 
constitute a reservoir of parasites for the inoculation of 
mosquitoes [26]. It is important to note that women in 
the IPTp-SP treatment group had a higher risk of para-
sitaemia compared to women in the ISTp-AL treat-
ment group. AL has been shown to be more effective at 
reducing gametocyte carriage and malaria transmission 
to mosquitoes compared to DHA-P [27]. ISTp with AL 
or other ACT regimens could reduce the incidence of 
malaria and anaemia, which could bring immense health 
and socioeconomic benefits. These advantages could be 
considered to outweigh the lower cost-effectiveness of 
the approach in the long term.
Previous trials [11, 13, 28, 29] have investigated alter-
native drug regimens and strategies to replace SP for 
intermittent preventive treatment of malaria in preg-
nancy. The most promising results are from Desai 
et al. [12] who found that IPTp with DHA-P was more 
Table 5 Comparison of number of women who 
experienced adverse events
IPTp‑SP ISTp‑AL p‑value Total
n (%) n (%) n (%)
Headache 35 (15.3) 34 (14.8) 0.929 69 (15)
Cough 23 (10) 17 (7.4) 0.323 40 (8.7)
Catarrh 15 (6.6) 15 (6.5) 0.966 30 (6.5)
Vomiting 7 (3.1) 9 (3.9) 0.641 16 (3.5)
Dizziness 6 (2.6) 10 (4.3) 0.319 16 (3.5)
Fever 2 (0.9) 10 (4.3) 0.022 12 (2.6)
Body pain 5 (2.2) 4 (1.7) 0.699 9 (2.0)
Itching 4 (1.7) 1 (0.4) 0.172 5 (1.1)
Nausea 1 (0.4) – 0.337 1 (0.2)
Rash – 1 (0.4) 0.338 1 (0.2)
Sleepiness – 1 (0.4) 0.338 1 (0.2)
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effective than ISTp with DHA-P or IPTp with SP at pre-
venting peripheral or placental malaria at delivery. This 
result suggests that ISTp as a strategy may not be suita-
ble for settings with high transmission. A recently pub-
lished trial [30], that evaluated four artemisinin-based 
combinations for the treatment of African pregnant 
women (second and third trimester) with malaria and 
found DHA-P to have the best efficacy and an accept-
able safety profile. However, AL was associated with the 
fewest adverse effects and an acceptable cure rate.
Moreover, the current levels of RDT sensitivity sug-
gest that the performance of presently available tests is 
inadequate for the screening of asymptomatic women 
who typically have low-density infections that are often 
missed by RDTs [12, 31]. There is also a concern about 
the absence of a prophylactic effect in women who test 
negative. This allows low-density infections to persist 
and increases the chance of new infections occurring 
between scheduled antenatal visits.
The WHO recently recommended the continued use 
of IPTp-SP for the prevention of MiP as there is not suf-
ficient evidence to suggest that it be replaced by ISTp 
or any other drug regimen replacing SP for use as IPTp 
[32].
ISTp remains a valuable approach to the control of 
MiP that needs to be further explored. IST may have 
other malaria control applications in endemic countries 
as they approach pre-elimination phase of malaria con-
trol, characterized by low-density infections in asymp-
tomatic carriers. The intermittent screening may serve 
as a malaria surveillance tool for monitoring population 
malaria levels. ISTp as an approach to control malaria 
in pregnancy may be more effective when highly sensi-
tive RDTs become available and if treatment can be with 
a single dose regimen, preferably produced from non-
artemisinin derivatives, but effective against gametocyte. 
This will ensure therapy can be directly observed at the 
antenatal clinic. The use of a non-artemisinin-based drug 
would prevent the potential development of artemisinin 
resistance.
Conclusions
This study showed non-inferiority of ISTp-AL to IPTp-
SP for preventing maternal anaemia in pregnant women 
in an area of high malaria transmission and moderate SP 
resistance. ISTp remains one of the potential alternatives 
to IPTp-SP, and its relevance will become more evident 
when the sensitivity of current generation of RDTs are 
improved beyond present levels. In the meantime, high 
priority must be given to identifying safe and cost-effec-
tive alternatives to SP for use in IPTp.
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